The treatment landscape for relapsed multiple myeloma has expanded considerably in recent years, as numerous agents with new mechanisms of action have been introduced, increasing responses even in advanced disease and prolonging survival. The wealth of novel regimens comes with the challenges of balancing toxicities and aligning a regimen with the biology of the myeloma and the nature of the relapse in conjunction with patient treatment history and personal preference. Herein, we provide an overview of treatment options for both early and late relapsing disease as well as a discussion of the role of emerging immune-based therapies.
When and How to Treat Relapsed Multiple Myeloma
Bertamini, Luca;Gay, Francesca;
2021-01-01
Abstract
The treatment landscape for relapsed multiple myeloma has expanded considerably in recent years, as numerous agents with new mechanisms of action have been introduced, increasing responses even in advanced disease and prolonging survival. The wealth of novel regimens comes with the challenges of balancing toxicities and aligning a regimen with the biology of the myeloma and the nature of the relapse in conjunction with patient treatment history and personal preference. Herein, we provide an overview of treatment options for both early and late relapsing disease as well as a discussion of the role of emerging immune-based therapies.File | Dimensione | Formato | |
---|---|---|---|
[PUBLISHED Vsn.] Nathwani et al - 2021 - ASCO Educational Nook - edbk_320129.pdf
Accesso riservato
Descrizione: [PUBLISHED Vsn.] Nathwani et al. Am Soc Clin Oncol Educ Book . 2021 Mar;41:358-375. doi: 10.1200/EDBK_320129.
Tipo di file:
PDF EDITORIALE
Dimensione
683.81 kB
Formato
Adobe PDF
|
683.81 kB | Adobe PDF | Visualizza/Apri Richiedi una copia |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.